Exenatide offers glucose benefits in type 1 diabetes

08/16/2013 | MedPage Today (free registration)

Type 1 diabetes patients who took exenatide prior to a mixed meal tolerance test attained a 33% reduction in glucose excursion and delays in gastric emptying, according to a small study in Diabetes Care. However, the drug did not appear to boost insulin secretion rates and did not show metabolic effects when taken before an intravenous glucose tolerance test, researchers said.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC